Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Charles Rudin
OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature
Oncologist
Cancer Research
Medicine
Oncology
Related publications
Prognostic Value of Delta‑like Protein 3 Combined With Thyroid Transcription Factor‑1 in Small‑cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
Preclinical Evaluation of a GFRA1 Targeted Antibody-Drug Conjugate in Breast Cancer
Oncotarget
Oncology
Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)
Oncologist
Cancer Research
Medicine
Oncology
Single‐Agent Paclitaxel in the Treatment of Advanced Non‐Small Cell Lung Cancer
Oncologist
Cancer Research
Medicine
Oncology
Tumor Stroma–targeted Antibody-Drug Conjugate Triggers Localized Anticancer Drug Release
Journal of Clinical Investigation
Medicine
Commentary on “Gemcitabine: Single‐Agent and Combination Therapy in Non‐Small Cell Lung Cancer”
Oncologist
Cancer Research
Medicine
Oncology
Single Agent Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer. Phase II Study
Research in Oncology
Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients With Small Cell Lung Cancer
OncoTargets and Therapy
Oncology
Pharmacology
Antibody Drug Conjugates (ADC) Charged With HDAC Inhibitor for Targeted Epigenetic Modulation
Chemical Science
Chemistry